| Popis: |
Intravenous (IV) ketamine has been shown to have rapid antidepressant effects in individuals with treatment-resistant depression (TRD). This treatment protocol describes a clinical method for use of subcutaneous (SC) and intramuscular (IM) racemic ketamine in individuals with TRD, developed by a team at the University of British Columbia (UBC), UBC Hospital, and Vancouver General Hospital. The use of SC and IM ketamine may be more feasible in clinical settings than IV ketamine and provide better access to this novel treatment. |
